Literature DB >> 15134624

Comparative pharmacokinetics of 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery.

Michael Vavra1, M Jaffer Ali, Eric W-Y Kang, Yot Navalitloha, Allison Ebert, Cathleen V Allen, Dennis R Groothuis.   

Abstract

We compared tissue and plasma pharmacokinetics of 14C-sucrose in subcutaneous RG-2 rat gliomas after administration by 3 routes, intravenous bolus (i.v.-B; 50 microCi over 30 s), continuous i.v. infusion (i.v.-C, 50 microCi at a constant rate), and convection-enhanced delivery (CED, 5 microCi infused at a rate of 0.5 microl/min), and for 3 experimental durations, 0.5, 2, and 4 h. Plasma, tumor, and other tissue samples were obtained to measure tissue radioactivity. Plasma radioactivity in the CED group increased exponentially and lagged only slightly behind the IV-C group. After 90 min, plasma values were similar in all. Mean tumor radioactivity was 100 to 500 times higher in the CED group at each time point than in the i.v.-B and i.v.-C groups. Tumor radioactivity was homogeneous in the i.v. groups at 0.5 h and inhomogeneous at 1 and 2 h. In CED, radioactivity distribution was inhomogeneous at all 3 time points; highest concentrations were in tissue around tumor and in necrosis, while viable tumor contained the lowest and sometimes negligible amounts of isotope. Systemic tissue radioactivity values were similar in all groups. Efflux of 14C-sucrose from tumors was evaluated in intracerebral tumors (at 0.5, 1, 2, and 4 h) and subcutaneous tumors (at 0 to 0.5 h). Less than 5% of 14C activity remained in intracerebral tumors at each time point. The efflux half-time from the subcutaneous tumors was 7.3 +/- 0.7 min. These results indicate rapid efflux of drug from brain tumor and marked heterogeneity of drug distribution within tumor after CED administration, both of which may be potentially limiting factors in drug delivery by this method.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15134624      PMCID: PMC1871980          DOI: 10.1215/s1152851703000449

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  25 in total

1.  Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas.

Authors:  Weilian Yang; Rolf F Barth; Dianne M Adams; Michael J Ciesielski; Robert A Fenstermaker; Supriya Shukla; Werner Tjarks; Michael A Caligiuri
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

2.  Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft.

Authors:  P E Kristjansen; Y Boucher; R K Jain
Journal:  Cancer Res       Date:  1993-10-15       Impact factor: 12.701

3.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy.

Authors:  Y Boucher; L T Baxter; R K Jain
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

Review 4.  Vascular and interstitial barriers to delivery of therapeutic agents in tumors.

Authors:  R K Jain
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

5.  Regional measurements of blood flow in experimental RG-2 rat gliomas.

Authors:  D R Groothuis; J F Pasternak; J M Fischer; R G Blasberg; D D Bigner; N A Vick
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

6.  Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas.

Authors:  D R Groothuis; J M Fischer; J F Pasternak; R G Blasberg; N A Vick; D D Bigner
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

7.  Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo.

Authors:  Carlo Giussani; Giorgio Carrabba; Mauro Pluderi; Valeria Lucini; Marilou Pannacci; Dario Caronzolo; Francesco Costa; Matteo Minotti; Giustino Tomei; Roberto Villani; Rona S Carroll; Andreas Bikfalvi; Lorenzo Bello
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

8.  Interstitial hypertension in human breast and colorectal tumors.

Authors:  J R Less; M C Posner; Y Boucher; D Borochovitz; N Wolmark; R K Jain
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

9.  Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse.

Authors:  Y Boucher; R K Jain
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

Review 10.  Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection.

Authors:  L T Baxter; R K Jain
Journal:  Microvasc Res       Date:  1989-01       Impact factor: 3.514

View more
  19 in total

Review 1.  Convection-Enhanced Delivery.

Authors:  A M Mehta; A M Sonabend; J N Bruce
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

2.  Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors.

Authors:  Yot Navalitloha; Erica S Schwartz; Elizabeth N Groothuis; Cathleen V Allen; Robert M Levy; Dennis R Groothuis
Journal:  Neuro Oncol       Date:  2006-06-14       Impact factor: 12.300

Review 3.  Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy.

Authors:  Mamta Wankhede; Alexandros Bouras; Milota Kaluzova; Costas G Hadjipanayis
Journal:  Expert Rev Clin Pharmacol       Date:  2012-03       Impact factor: 5.045

4.  Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma.

Authors:  Jyoti Sharma; Hua Lv; James M Gallo
Journal:  Cancer Res       Date:  2013-06-24       Impact factor: 12.701

5.  Safety and efficacy of convection-enhanced delivery of ACNU, a hydrophilic nitrosourea, in intracranial brain tumor models.

Authors:  Shin-ichiro Sugiyama; Yoji Yamashita; Toshio Kikuchi; Ryuta Saito; Toshihiro Kumabe; Teiji Tominaga
Journal:  J Neurooncol       Date:  2006-09-20       Impact factor: 4.130

6.  Isolation of drug delivery from drug effect: problems of optimizing drug delivery parameters.

Authors:  Mir J Ali; Yot Navalitloha; Michael W Vavra; Eric W-Y Kang; Andrea C Itskovich; Peter Molnar; Robert M Levy; Dennis R Groothuis
Journal:  Neuro Oncol       Date:  2006-03-08       Impact factor: 12.300

7.  Canine model of convection-enhanced delivery of cetuximab-conjugated iron-oxide nanoparticles monitored with magnetic resonance imaging.

Authors:  Simon Platt; Edjah Nduom; Marc Kent; Courtenay Freeman; Revaz Machaidze; Milota Kaluzova; Liya Wang; Hui Mao; Costas G Hadjipanayis
Journal:  Clin Neurosurg       Date:  2012

Review 8.  Multifunctional nanoparticles for brain tumor imaging and therapy.

Authors:  Yu Cheng; Ramin A Morshed; Brenda Auffinger; Alex L Tobias; Maciej S Lesniak
Journal:  Adv Drug Deliv Rev       Date:  2013-09-20       Impact factor: 15.470

9.  188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas.

Authors:  E Allard; F Hindre; C Passirani; L Lemaire; N Lepareur; N Noiret; P Menei; J-P Benoit
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

10.  Anatomic compression caused by high-volume convection-enhanced delivery to the brain.

Authors:  Francisco Valles; Massimo S Fiandaca; John Bringas; Peter Dickinson; Richard LeCouteur; Robert Higgins; Mitchel Berger; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurosurgery       Date:  2009-09       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.